Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk

WSJ33minutes ago

JonesTrading Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsDec 5 16:31 ET · Ratings

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaDec 5 16:05 ET

America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday

BenzingaDec 5 10:15 ET

Capricor Therapeutics, Inc. (NASDAQ:CAPR): Are Analysts Optimistic?

Simply Wall StDec 5 07:46 ET

Capricor Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswireDec 2 16:15 ET